Amsterdam, the Netherlands Tuesday, April 29, 2025, 10:00 Hrs [IST] ...

Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. 4,5 Here, we review ...

Argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) ...

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.

Due to the autoimmune etiology of this disorder, IV immunoglobulin (IVIg) or plasma exchange (PE) are the first-line treatments in addition to management of ventilatory failure. IVIg is more ...

Published in the peer-reviewed journal mAbs, the study presents nipocalimab's high-affinity binding to the neonatal Fc receptor (FcRn) and its capability to significantly reduce IgG levels ...

Although the polymeric immunoglobulin receptor ... Azuma, Science University, Tokyo), and human IgM-Fc (Rockland, Gilbertsville, PA) were used. Monoclonal antibodies to human CD3, CD45 and ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised ...